Minerva Advisors’s NextCure NXTC Stock Holding History

Minerva Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,643	Closed	-$46.9K	–	67
2023 Q1	$46.9K	Hold	2,643	–	–	0.03%	67
2022 Q4	$44.7K	Hold	2,643	–	–	0.03%	65
2022 Q3	$87K	Hold	2,643	–	–	0.07%	65
2022 Q2	$149K	Hold	2,643	–	–	0.11%	63
2022 Q1	$154K	Hold	2,643	–	–	0.1%	63
2021 Q4	$190K	Buy	+2,643	New	+$221K	0.11%	69

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Minerva Advisors's NXTC Position: Q2 2023 in Review

Minerva Advisors sold out of NextCure (NXTC) in Q2 2023, closing a stake of 2,643 shares — an estimated $46.9K sold.

Minerva Advisors first reported a position in NXTC in Q4 2021 and held it in 6 quarters. The position peaked at $190K in Q4 2021. 43 funds tracked by Wall St. Rank hold NXTC as of Q2 2023.

Minerva Advisors reported no remaining NextCure position as of Q2 2023 after selling out during the quarter.
Minerva Advisors sold 2,643 NextCure shares in Q2 2023, an estimated $46.9K.
Minerva Advisors first reported a position in NextCure in Q4 2021 and held it in 6 quarters.
Minerva Advisors's NextCure position peaked at $190K in Q4 2021.
43 funds tracked by Wall St. Rank held NextCure as of Q2 2023.

Based on Minerva Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.